News

  1. Aegis Sciences Corporation Further Expands Testing for Novel Psychoactive Substances

    NASHVILLE, TN. (September 12, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion…

    NASHVILLE, TN. (September 12, 2023) – Aegis Sciences Corporation, a health care testing lab based in Nashville, TN, is pleased to announce another expansion of novel psychoactive substance (NPS) testing for its clients. The NPS test menu includes expanded offerings for designer opioids, designer benzodiazepines, synthetic cannabinoids, synthetic stimulants, hallucinogens/dissociatives, and other substances…

  2. Aegis receives Distinguished Abstract recognition

    The study, Evidence of Missed Novel Psychoactive Substances (NPS) in Unexpected Fentanyl Positives, by Aegis Sciences Corporation was recognized by the…

    The study, Evidence of Missed Novel Psychoactive Substances (NPS) in Unexpected Fentanyl Positives, by Aegis Sciences Corporation was recognized by the AACC Annual Scientific Meeting & Clinical Lab Expo.Each year, a group of Academy fellows reviews the abstracts submitted to the AACC Annual Scientific Meeting & Clinical Lab Expo and selects several for distinction. The study evaluated how common novel…

  3. The Results of our Client Satisfaction Survey 2023

    Aegis Sciences Corporation has achieved great success with its sales and service according to our latest Client Satisfaction Survey.  Our toxicology services…

    Aegis Sciences Corporation has achieved great success with its sales and service according to our latest Client Satisfaction Survey.  Our toxicology services provide insights to help clinicians identify medication compliance, explore causes of non-adherence, and reduce risk for adverse events and overdose. Providers agree that our services make a difference for their practice and for their patients. “I…

  4. Aegis Selected as a UnitedHealthcare Preferred Lab Network Provider for the Second Year in a Row

    NASHVILLE, Tenn., July 1, 2023 – Aegis is pleased to announce that following a rigorous review process, it will continue to participate as a UnitedHealthcare…

    NASHVILLE, Tenn., July 1, 2023 – Aegis is pleased to announce that following a rigorous review process, it will continue to participate as a UnitedHealthcare Preferred Lab Network (PLN) provider for 2023-2024. The Preferred Lab Network consists of currently contracted independent, freestanding laboratory care providers that have met higher standards for access, cost, data, quality, and service. For…

  5. The Tip of the Iceberg

    The Tip of the Iceberg

    Aegis recent panelist, Ryan S. Alexander, DO, MPH, has released an op-ed where he expresses the need for testing in an uncertain drug landscape.

    Aegis recent panelist, Ryan S. Alexander, DO, MPH, has released an op-ed where he expresses the need for testing in an uncertain drug landscape.

  6. Xylazine Use Shows Need For Testing

    Xylazine Use Shows Need For Testing

    Aegis provider and recent panelist, Leigh Brooks, APRN, FNP-C, has released an op-ed where she shares her firsthand experience with dangerous drugs like…

    Aegis provider and recent panelist, Leigh Brooks, APRN, FNP-C, has released an op-ed where she shares her firsthand experience with dangerous drugs like xylazine and how comprehensive testing and education can make an impact.

  7. Testing is Crucial in the Fight Against Xylazine

    Testing is Crucial in the Fight Against Xylazine

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he expresses the importance of clinical definitive testing for…

    Aegis Clinical Pharmacist, Andrew Holt, Pharm.D., BCMAS, CPGx, has released an op-ed where he expresses the importance of clinical definitive testing for fentanyl-xylazine mixtures, an emerging threat to the United States.

  8. Nashville lab ramps up xylazine testing increasingly detected in drug overdoses

    The Biden Administration recently designated the fentanyl-xylazine combination as an emerging national threat. Aegis Sciences Corporation in Nashville…

    The Biden Administration recently designated the fentanyl-xylazine combination as an emerging national threat. Aegis Sciences Corporation in Nashville has been on the forefront of testing for the deadly compound. Dr. Josh Schrecker, senior director of clinical affairs talked with NewsChannel 5 about how providers utilize test results. Early identification of these compounds is key to appropriate treatment…

  9. Regina Sweeney, Aegis Sciences Corporation Wins Bronze Stevie® Award in 2023 Stevie Awards for Sales & Customer Service

    NASHVILLE, Tenn., March 6, 2023 – Regina Sweeney, Vice President of Client Relations, Aegis Sciences Corporation has been presented with a Bronze Stevie®…

    NASHVILLE, Tenn., March 6, 2023 – Regina Sweeney, Vice President of Client Relations, Aegis Sciences Corporation has been presented with a Bronze Stevie® Award in the Sales & Customer Service category in the 17th annual Stevie Awards for Sales & Customer Service. The Stevie Awards for Sales & Customer Service are the world’s top honors for customer service, contact center, business development and…

  10. Surveillance and Testing to Stem the Tide of the Next Opioid Drug Crisis

    Surveillance and Testing to Stem the Tide of the Next Opioid Drug Crisis

    Aegis recent panelist, Alex J. Krotulski, PhD, released an op-ed that is an exploration into the identification of new and emerging synthetic opioids.

    Aegis recent panelist, Alex J. Krotulski, PhD, released an op-ed that is an exploration into the identification of new and emerging synthetic opioids.